STICH3C: Rationale and Study Protocol.
Stephen E Fremes, Guillaume Marquis-Gravel, Mario F L Gaudino...
https://pubmed.ncbi.nlm.nih.gov/37582169/Actively Recruiting
Led by Sunnybrook Health Sciences Centre · Updated on 2026-10-19
754
Participants Needed
46
Research Sites
34 weeks
Total Duration
Researchers are comparing two methods of restoring blood flow to the heartpercutaneous coronary intervention PCI and coronary artery bypass grafting CABGin patients with multivessel or left main coronary artery disease and reduced heart pumping function known as ischemic left ventricular dysfunction. This international, randomized trial aims to determine which method better reduces death, stroke, heart attack, urgent repeat procedures, or heart failure hospitalizations over a median follow-up of five years. The study addresses the current lack of strong evidence comparing these modern revascularization approaches in this vulnerable patient group. Participants will be randomly assigned to receive either PCI or CABG, with treatments planned by a specialized Heart Team including cardiologists and cardiac surgeons. PCI will follow contemporary best practices like using drug-eluting stents and advanced imaging. CABG will be tailored based on individual anatomy and health, with specific surgical techniques recommended. Initial revascularization is expected within two weeks of randomization, and staged PCI procedures within 90 days. Enrollment spans three years, with total study duration of seven years and median follow-up of five years. During the study, participants will undergo regular assessments including clinical evaluations, imaging, and monitoring for adverse events. The main outcomes measured include a composite of death, stroke, heart attack, urgent repeat procedures, and heart failure readmissions. Secondary outcomes track early risks, hospitalizations, and patient-reported health status throughout the follow-up. Safety and efficacy data will be collected up to the studys completion, providing comprehensive insights into treatment impacts over time.
CONDITIONS
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)
S
Stephen Fremes, MD,MSc,FRCSC
R
Reena Karkhanis, MBBS,DA,MSc
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Sunnybrook Health Sciences Centre
Lead Sponsor
Canadian Institutes of Health Research (CIHR)
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Percutaneous coronary intervention (PCI) | Coronary artery bypass grafting (CABG) | Guideline‑based Heart Team decision-making |
|---|---|---|---|
| What the option is | Percutaneous coronary intervention using modern techniques including physiological and intravascular guidance, new‑generation drug‑eluting stents, calcification treatment, and trans‑radial access. | Coronary artery bypass graft surgery tailored per patient anatomy, including internal thoracic artery graft to LAD, optional multi‑arterial grafting, and surgeon‑determined use of on‑ vs. off‑pump techniques. | Current guideline‑recommended Heart Team approach individualizes choice between PCI and CABG based on symptoms, coronary anatomy, surgical risk and patient factors. |
| Role in the trial | One of two randomized procedural arms. | The other randomized procedural arm. | Represents how revascularization decisions are generally made outside of trial setting. |
| Primary intended use | To revascularize multivessel coronary disease in ischemic cardiomyopathy patients. | To surgically revascularize multivessel coronary disease in ischemic cardiomyopathy patients. | Guideline‑based revascularization decision for patients fitting similar criteria outside trial. |
| How it is performed | Performed percutaneously via arteries using modern stents and intravascular imaging under physiological guidance. | Surgically grafts vessels using internal thoracic artery and optionally multiple arteries; on‑ or off‑pump as determined by surgeon. | Heart Team evaluates and recommends either PCI or CABG based on clinical and anatomical considerations. |
| Evidence on outcomes | Outcome data are not yet available from this trial. | Outcome data are not yet available from this trial. | Prior observational and registry analyses suggest CABG may offer long‑term survival benefit over PCI in ischemic cardiomyopathy. |
| Important risks | Risks not yet reported for this trial. | Risks not yet reported for this trial. | Registry data indicate CABG may be associated with higher peri‑procedural stroke and longer hospital stay compared to PCI. |
| Important limitations | No outcome or safety data yet available from this investigational arm. | No outcome or safety data yet available from this surgical arm. | Evidence comparing PCI to CABG in current‑era heart failure patients remains limited and largely observational. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 to 2 visits
Duration - Up to 3 months
Participants receive either PCI or CABG to restore blood flow based on random assignment. Treatments are planned by a Heart Team and performed within a few weeks of enrollment.
Initial procedure within 2 weeks; staged PCI within 90 days
Duration - Median of 5 years
Participants are monitored for up to 5 years to assess clinical outcomes, safety, and patient-reported health status through regular visits and assessments.
Regular follow-up visits ongoing
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Stephen E Fremes, Guillaume Marquis-Gravel, Mario F L Gaudino...
https://pubmed.ncbi.nlm.nih.gov/37582169/Sunnybrook Health Sciences Centre
Lead Sponsor
Canadian Institutes of Health Research (CIHR)
Collaborating Sponsor